Compare Becton Dickinson and Co (BDX) vs Intuit Inc. (INTU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs Intuit Inc. — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $41.51B), while Intuit Inc. trades at $285 (market cap $77.26B). The key difference: Intuit Inc. is the larger of the two by market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | INTU | |
|---|---|---|
Market Cap | $41.51B | $77.26B |
Sector | Health | Technology |
52-Week High | $185.39 | $807.39 |
52-Week Low | $135.49 | $255.07 |
Enterprise Value | $57.97B | $75.71B |
Dividend Yield | 2.79% | 1.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
Intuit (INTU) trades at $289.73, up 5.37% in the last session, with a bullish technical signal and strong support at $284. The company reported robust earnings, beating estimates for Q3 2025, Q4 2025, and Q1 2026, with revenue growth from $18.83B in 2025 to a projected $20.9B in 2026. Profit margins improved to 21.91% net income margin, while valuation ratios like P/E of 17.23 and P/S of 3.78 indicate reasonable pricing. However, recent news highlights a 20% stock drop and securities fraud investigations, adding volatility.
Outlook remains positive due to consistent earnings beats and AI-driven growth, but risks include legal scrutiny and competitive pressures. Analysts maintain a 71.11% buy rating with a $422.88 consensus target, suggesting potential upside if the company navigates current challenges effectively.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →
